Study of Nivolumab Plus Ipilimumab, Ipilimumab or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)

The purpose of this study is to determine whether Nivolumab plus Ipilimumab has preliminary evidence of safety and effectiveness in the treatment of participants with metastatic castration-resistant prostate cancer who have progressed after prior Docetaxel-containing regimen.


Study Type: Interventional  (Clinical Trial)
Estimated Enrollment: 618 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Trial of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer
Actual Study Start Date: March 17, 2017
Estimated Primary Completion Date: June 28, 2021
Estimated Study Completion Date: May 30, 2022

Arms:
- Experimental: Cohort A (Arm A)
- Experimental: Cohort B (Arm B)
- Experimental: Cohort C (Arm C)
- Experimental: Cohort D (Arm D1)
- Experimental: Cohort D (Arm D2)
- Experimental: Cohort D (Arm D3)
- Experimental: Cohort D (Arm D4)